News re: Upcoming conferencesLet's hope that this is the news/results that will start "the ride"...
Data
"ConjuChem Will Deliver One Oral Presentation, One Poster Presentation and One Abstract Publication at The American Diabetes Association 65th Scientific Sessions in San Diego
10:04 EDT Wednesday, June 08, 2005
MONTREAL, June 8 /CNW/ - ConjuChem Inc. (TSX:CJC) today announced details of presentations at The American Diabetes Association 65th Scientific Sessions in San Diego, CA, from June 10 to 14, 2005.
One oral presentation, one poster presentation and one abstract publication will be delivered at this meeting:
Effects of DAC(TM):GLP-1 (CJC-1131) on Glycemic Control and Weight Over 12 Weeks in Metformin-Treated Patients with Type 2 Diabetes
This oral presentation will provide details on the Phase 2 clinical trial concluding that CJC-1131 in combination with Metformin significantly reduced HbA1c without increasing the risk of hypoglycemia in patients previously unable to attain glycemic control treated with Metformin or Metformin and Sulfonylurea. Dr. Robert E. Ratner, M.D. (VP Scientific Affairs, MedStar Research Institute, MD) will be making this presentation on Friday, June 10, 2005 at 2:00 p.m. in SDCC - Room 20BC of the San Diego Convention Center. Professor Daniel J. Drucker, M.D. (Director of Banting and Best Diabetes Institute, ON), Professor Jean-Pierre Hallé, M.D. (University of Montreal, QC), Professor Stuart A. Ross, M.D. (University of Calgary, AB), and Professor Mark S. Kipnes, M.D. (University of Texas Health Sciences Center at San Antonio, TX) are among the co-authors of this presentation.
CJC-1525/CJC-1575: Long Lasting DAC(TM) Insulin Analogues for Basal
Glycemic Control
This poster will provide details on experiments conducted on mice, rats, and dogs demonstrating long acting control of glucose after a single or multiple injection(s) of DAC(TM):Insulin. DAC(TM):Insulin has been selected for further development to advance to the clinical stage in 2006. Dr. Martin Robitaille, Ph.D. (ConjuChem, QC) and Ms. Stella Wen (ConjuChem, QC) will be presenting the poster on Monday, June 13, 2005 from 12:00 p.m. to 2:00 p.m.
Lack of Immunogenicity Following Repeated Administration of CJC-1131, a Drug-Affinity Complex (DAC(TM)) GLP-1, in Monkeys
This abstract summarizes the immunogenicity study conducted in Cynomolgus monkeys over 6 months concluding that the lack of immunogenicity of CJC-1131 in monkeys together with similar data from studies with CJC-1131 or with other DAC(TM) compounds augments the safety profile of the DAC(TM) technology. This abstract will be published in the 65th Scientific Sessions Abstract Book, the June supplement to the journal Diabetes."